- Global Pharma News & Resources

UCB launches Community Health Fund to support vulnerable young people post-COVID-19 crisis

UCB has launched a 3 million Euro (£2.7 million) Community Health Fund to support vulnerable people suffering as a result of the coronavirus pandemic.


The global Fund, established last month, aims to provide support for the most vulnerable people within the communities of the 36 countries in which UCB operates – including the UK, home to one of the company’s three global research and development hubs. And it is currently looking to help organisations supporting vulnerable young people (15-24 years) impacted by coronavirus in the UK.


Those running projects or undertaking social science research with a focus on young people from vulnerable communities –  including racial and ethnic minorities, refugees and asylum seekers, those with disabilities and certain health conditions, and those who are socio-economically disadvantaged –  are invited to apply for grants of up to 150,000 Euro (£130,000) through the Fund to support their initiatives.


Dan Coombes, General Manager UCB UK said: “COVID-19 represents the most severe public health crisis and the deepest economic downturn of the modern era, revealing challenges in health systems and economies around the world. These challenges will have the greatest impact on those most vulnerable in society and we are committed to supporting them where we can.


“In this first call for projects we are looking for applications from UK-based organisations or individuals working to understand and reduce the medium- and long-term impact of the COVID-19 pandemic on the wellbeing - physical, mental and social - of vulnerable young people.”


Applications for grants close on 30 September 2020. For more information and to apply for a research or support grant visit   

About the Community Health Fund

The UCB Community Health Fund is a 3 million Euro global fund established to help vulnerable people such as racial and ethnic minorities, children, older people, socio-economically disadvantaged persons, or those with certain medical conditions not related to our therapeutic areas or assets in the communities in which we operate.


Members of these vulnerable populations often have health conditions that are exacerbated by inadequate access to healthcare resources and the Fund aims to address these health disparities. Initially the focus will be on contributing to understanding and reducing the medium- and long-term impacts of the COVID-19 pandemic on vulnerable populations’ physical, mental, and social wellbeing.


The Fund is managed by the King Baudouin Foundation, an independent foundation based in Brussels, Belgium. It seeks to change society for the better and invests in inspiring projects and individuals.


The Fund will publish Calls for Projects that address the needs of specific vulnerable groups. An independent jury will assist in the selection of projects and award funding. The jury for each call will be selected by a management committee – working on a pro bono basis – which is composed of representatives from UCB, the King Baudouin Foundation, and an independent chair who is supported by a general secretary.


This first Call for Projects aims to understand and reduce the medium- and long-term impact of the COVID-19 pandemic on the wellbeing - physical, mental and social - of vulnerable young people (15-24 years old).


About UCB

UCB is a global biopharmaceutical company dedicated to discovering and developing treatments that aim to transform the lives of people living with neurological and immunological conditions.


Because there is no such thing as an ‘average patient’ we use the tools, channels and scientific advances at our disposal to develop a deep understanding of a disease and the real needs of patients.


Working in collaboration with leading researchers from academia, medical charities and industry we strive to deliver cutting-edge science, innovative drugs and practical solutions patients need to improve their quality of life.


We are inspired by patients. Driven by science.


Editor Details

  • Company:
    • UCB
  • Name:
    • UCB
Last Updated: 21-Sep-2020